Noticias y Actividades de Tevogen Bio
Presencia
Tevogen Bio es una empresa que cotiza bajo el símbolo de cotización TVGN (US).
Ejecutivos
Ver el organigrama con sus 16 ejecutivos principales
Biografías más buscadas en Tevogen Bio
- Ryan Saadi, Chairman of the Board and Chief Executive Officer
- Curtis Patton, Director
- Lindee Goh, Director
Recientes movimientos de ejecutivos en Tevogen Bio
- David Banko, se ha incorporado a la empresa como Global Head, Government Affairs and Patient Access (noticia publicada el 26 de marzo de 2025).
Crear su alerta
para seguir los movimientos de los ejecutivos en Tevogen Bio.
Biotecnología
Tevogen Bio tiene 2.350 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Genus (Reino Unido).
Popular M&A news in Biotecnología
- Transcarent and Accolade have merged (publicado el 9 de abril de 2025)..
- Kashiv BioSciences acaba de anunciar una recaudación de fondos de 150 millones de dólares. (publicado el 7 de abril de 2025).
- Atsena Therapeutics acaba de anunciar una recaudación de fondos de 150 millones de dólares. (publicado el 4 de abril de 2025).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Tevogen Bio
- Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
- Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company’s Mission
- Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump’s Initiative to Encourage Pharmaceutical Manufacturing in United States
- Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly’s Leading AI Biotechs
- Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast
- Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan
- Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO
- Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel
- Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations
- Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy
- View more press releases Close
Redes sociales sobre Tevogen Bio
- Tevogen Bio en Wikipedia, Google News y Yahoo Finance
- Tevogen Bio en LinkedIn, Twitter y YouTube
